Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Archive for January, 2012

‘Breakthrough’ startups reap investments from new early-stage fund

Wednesday, January 25th, 2012

Cambridge, Mass.-based Flagship Ventures recently launched the company's largest fund to date, raising $270 million for its life sciences funds, money that will add around 20 new biotechnology companies to Flagship's portfolio, according to officials. With the closing of the new fund, the company now has ...

Lifecycle modeling and simulation: poised to transform drug development

Thursday, January 19th, 2012

(editor's note: this is a special guest post from Quintiles) By Michael O’Kelly, Senior Biostatistics Director, Center for Statistics in Drug Development, Innovation, Quintiles To build their 1903 flyer, the Wright Brothers modeled and tested wing shapes in a wind tunnel to reduce costs. A century later, 800,000 simulation hours on the ...

Survey: Lack of funds, regulatory climate threaten biomedical industry

Friday, January 13th, 2012

Future growth for the biomedical industry faces growing and unprecedented threats, according to a newly released survey of CEOs from life sciences companies in California, the largest biomedical cluster in the world. The three biggest threats reported were access to capital, a burdensome and uncertain regulatory environment, and lack of ...

Biotech startup continues hot streak

Tuesday, January 10th, 2012

If you have been following some of the buzz out of the JP Morgan Healthcare Conference this week, access to traditional venture capital remains difficult for biomedical companies, particularly for biotech startups. Thus, opportunities to forge licensing agreements or corporate partnerships with large biopharma companies has become increasingly vital for startups ...

   
©2012 UBM Canon